Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Materials and Methods Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinicolaboratory factors, univariate and multivariable analyses for overall survival (OS) were performed. Results A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11 to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic disease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.36; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. Conclusion Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials.
Abstract
Purpose The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Materials and Methods Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinicolaboratory factors, univariate and multivariable analyses for overall survival (OS) were performed. Results A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11 to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic disease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.36; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. Conclusion Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials.
참고문헌 (28)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Hidalgo M, "Pancreatic cancer", N Engl J Med, 362, pp.1605~1617 (2010)
- Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
- Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Cartwright TH, "Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy", J Clin Oncol, 32(5S) (2014)
- Bachmann J, "Cachexia worsens prognosis in patients with resectable pancreatic cancer", J Gastrointest Surg, 12, pp.1193~1201 (2008)
- Davison KK, "Lean and weight stable : behavioral predictors and psychological correlates", Obes Res, 12, pp.1085~1093 (2004)
- Fearon K, "Definition and classification of cancer cachexia : an international consensus", Lancet Oncol, 12, pp.489~495 (2011)
- Dalal S, "Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation : a pilot study", J Pain Symptom Manage, 44, pp.181~191 (2012)
- Di Sebastiano KM, "Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients : the relationship with diabetes and anaemia", Br J Nutr, 109, pp.302~312 (2013)
- Tan BH, "Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer", Clin Cancer Res, 15, pp.6973~6979 (2009)
- Kim YS, "Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys", J Gerontol A Biol Sci Med Sci, 67, pp.1107~1113 (2012)
- Mourtzakis M, "A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care", Appl Physiol Nutr Metab, 33, pp.997~1006 (2008)
- Janssen I, "Low relative skeletal muscle mass(sarcopenia)in older persons is associated with functional impairment and physical disability", J Am Geriatr Soc, 50, pp.889~896 (2002)
- Brunelli A, "Internal validation of risk models in lung resection surgery : bootstrap versus training-and-test sampling", J Thorac Cardiovasc Surg, 131, pp.1243~1247 (2006)
- Grunkemeier GL, "Bootstrap resampling methods:something for nothing?", Ann Thorac Surg, 77, pp.1142~1144 (2004)
- Stocken DD, "Modelling prognostic factors in advanced pancreatic cancer", Br J Cancer, 99, pp.883~893 (2008)
- Marechal R, "Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer", Oncology, 73, pp.41~51 (2007)
- Wasan HS, "CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone", Br J Cancer, 101, pp.1162~1167 (2009)
- 이경주, "Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma", Yonsei Medical Journal, 54(3), pp.643~649 (2013), 연세대학교의과대학[DOI]
- Inal A, "Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin : retrospective analysis of a multicenter study", J BUON, 17, pp.102~105 (2012)
- Tas F, "Prognostic factors in pancreatic carcinoma : serum LDH levels predict survival in metastatic disease", Am J Clin Oncol, 24, pp.547~550 (2001)
- Faloppi L, "The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib", Oncotarget, 6, pp.35087~35094 (2015)
- Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on Sarcopenia in Older People", Age Ageing, 39, pp.412~423 (2010)
- Martin L, "Cancer cachexia in the age of obesity : skeletal muscle depletion is a powerful prognostic factor, independent of body mass index", J Clin Oncol, 31, pp.1539~1547 (2013)